A Case of Concurrent Metformin-Associated Lactic Acidosis and Euglycemic Diabetic Ketoacidosis
Abstract
BACKGROUND: Combination therapy with metformin and sodium-glucose cotransporter 2 (SGLT2) inhibitors is strongly recommended for adults with type 2 diabetes mellitus who have inadequate glycemic control. These inhibitors are particularly indicated for patients with a history or high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. Consequently, the number of patients receiving both metformin and SGLT2 inhibitors is expected to increase. However, these treatments pose a risk of life-threatening acidoses, specifically metformin-associated lactic acidosis (MALA) and euglycemic diabetic ketoacidosis (euDKA), which require prompt differentiation and distinct treatments.
CASE REPORT: We present the case of a woman in her 50s with chronic heart failure who had been treated for type 2 diabetes for 15 years. After dehydration caused by working in hot conditions and fluid restriction, she presented with dehydration, fatigue, respiratory distress, hypotension, tachypnea, hypothermia, acute renal failure, hypoglycemia, and severe metabolic acidosis. Despite supportive care, lactic acidosis persisted, leading to a diagnosis of MALA. Hemodialysis improved lactate levels, but a persistent anion gap and elevated β-hydroxybutyrate level confirmed euDKA. Metabolic abnormalities resolved with continuous insulin infusion and the patient was discharged without sequelae. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: The combination of MALA and euDKA…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.